BRFAA - Biomedical Research Foundation Academy Of Athens
Biomedical Research Foundation Academy Of AthensAcademy Of Athens

Publications

  1. Kanaki, Z., Smina, A., Chandrinou, C., Koukouzeli, F. E., Ntounias, Y., Paschalidis, N., ..., Tamvakopoulos, C., & Klinakis, A. (2023). Printed cisplatin on microneedle arrays for transdermal delivery enhances olaparib-induced synthetic lethality in a mouse model of homologous recombination deficiency. International Journal of Bioprinting, 9(6), 0048.
  2. Chatzisideri, T., Leonidis, G., Karampelas, T., Skavatsou, E., Velentza-Almpani, A., Bianchini, F., ..., Tamvakopoulos, C., & Sarli, V. (2022). Integrin-Mediated Targeted Cancer Therapy Using c (RGDyK)-Based Conjugates of Gemcitabine. Journal of Medicinal Chemistry, 65(1), 271-284.
  3. Orfanou, I. M., Argyros, O., Papapetropoulos, A., Tseleni-Balafouta, S., Vougas, K., & Tamvakopoulos, C. (2021). Discovery and pharmacological evaluation of STEAP4 as a novel target for HER2 overexpressing breast cancer. Frontiers in Oncology, 11, 608201.
  4. Skavatsou, E., Semitekolou, M., Morianos, I., Karampelas, T., Lougiakis, N., Xanthou, G., & Tamvakopoulos, C. (2021). Immunotherapy combined with metronomic dosing: An effective approach for the treatment of nsclc. Cancers, 13(8), 1901.
  5. Vrettos, E. I., Karampelas, T., Sayyad, N., Kougioumtzi, A., Syed, N., Crook, T., ..., Tamvakopoulos, C., & Tzakos, A. G. (2021). Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer. European Journal of Medicinal Chemistry, 211, 113018.
  6. Soulele, K., Karampelas, T., Tamvakopoulos, C., & Macheras, P. (2021). Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation. Pharmaceutical Research, 38(8), 1419-1428.
  7. Pyrillou, K., Chairakaki, A. D., Tamvakopoulos, C., & Andreakos, E. (2018). Dexamethasone induces ω3-derived immunoresolvents driving resolution of allergic airway inflammation. Journal of allergy and clinical immunology, 142(2), 691-695.
  8. Argyros, O., Karampelas, T., Asvos, X., Varela, A., Sayyad, N., Papakyriakou, A., ... & Tamvakopoulos, C. (2016). Peptide–Drug Conjugate GnRH–Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth. Cancer Research, 76(5), 1181-1192.
  9. Stellas, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., ..., Tamvakopoulos, C., Klinakis, A., & Efstratiadis, A. (2014). Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. Journal of the National Cancer Institute, 106(12), dju320.
  10. Katsila, T., Siskos, A. P., & Tamvakopoulos, C. (2012). Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass spectrometry reviews, 31(1), 110-133.
  11. Zhu, L., Tamvakopoulos, C., Xie, D., Dragovic, J., Shen, X., Fenyk-Melody, J. E., ... & Roy, R. S. (2003). The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase-activating polypeptide-(1–38). Journal of Biological Chemistry, 278(25), 22418-22423.
  12. Van der Ploeg, L. H., Martin, W. J., Howard, A. D., Nargund, R. P., Austin, C. P., Guan, X., ... & MacIntyre, D. E. (2002). A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences, 99(17), 11381-11386.

Constantin Tamvakopoulos' Pubmed